Coya Therapeutics, Inc. (COYA)
Nasdaq · Healthcare · Biotechnology
$4.85+0.83%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $114M
- 52-week range
- $3.71 – $7.75
- 52-week change
- −26.00%
- EPS (trailing)
- −$1.07
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $7.9M (+123.57%)
- Net income
- −$21.2M
- Operating margin
- −283.9%
- Diluted EPS
- −$1.27
From the company’s annual report on SEC EDGAR.
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr.
Headquarters: Houston, United States · 8 employees · coyatherapeutics.com